| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| General and administrative | 650,277 | - | ||
| Research and development | 136,432 | - | ||
| Total operating expenses | 786,709 | - | ||
| Operating loss | -786,709 | -633,783 | ||
| Interest expense | 22,713 | 23,596 | ||
| Foreign currency gain (loss) | -539 | -6,092 | ||
| Other expense | 4,000 | - | ||
| Taxes | -50 | -113 | ||
| Total other income (expense) | -27,302 | -29,801 | ||
| Net loss | -814,011 | -663,584 | ||
| Weighted average number of common shares outstanding | 281,463,410 | 281,123,410 | ||
REGENEREX PHARMA, INC. (RGPX)
REGENEREX PHARMA, INC. (RGPX)